Please ensure Javascript is enabled for purposes of website accessibility

Why Amicus Therapeutics Inc. Rocketed Higher Today

By Brian Orelli, PhD - Jul 11, 2017 at 12:53PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The FDA reversed itself and agreed to accept the biotech's current data as a basis for considering approval of Fabry disease treatment migalastat.

What happened

Amicus Therapeutics (FOLD 2.16%) shares were up 25% at 12:05 p.m. EDT after the biopharmaceutical company disclosed  that the Food and Drug Administration is willing to look at the data it currently has to consider approving its Fabry disease treatment, migalastat.

So what

Things looked a little grim for the company last November, after the FDA told Amicus that it would need more data on how migalastat affects gastrointestinal symptoms before it would consider approving the drug. Considering that Amicus hadn't even started the new trial that would be required to gather that data, it looked like the FDA's decision had pushed back a potential approval by a few years.

But after a few more discussions with regulators, Amicus was able to convince the agency that its current data was good enough to warrant immediate consideration. It appears the company connected the dots for the agency, making the case that since the drug lowers GL-3, and GL-3 is believed to be what causes the pain, kidney failure, heart disease, and strokes, seen in Fabry disease patients, migalastat should help patients.

That logic had been enough to convince regulators to approve the drug in the European Union, where it goes by the brand name of Galafold. The drug is also approved in Israel and Switzerland.

Accepted ink stamp

Image source: Getty Images.

Now what

Normally, the FDA accepting a marketing application doesn't say much about a drug's approvability, but considering the amount of time the agency has spent deciding whether Amicus has enough data just to apply, an approval of migalastat now that it has cleared that hurdle seems highly likely.

Unfortunately, there's no discount to be had here; shares are trading higher than they were in November before the initial announcement about the FDA wanting additional data.

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Amicus Therapeutics, Inc. Stock Quote
Amicus Therapeutics, Inc.
FOLD
$12.32 (2.16%) $0.26

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.